The World Health Organization’s targets for eliminating hepatitis C virus by 2030 have been deemed ambitious by many. However, we believe they are achievable, provided they are supported by global commitment.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study
Addiction Science & Clinical Practice Open Access 25 May 2023
-
Peer-facilitated treatment access for hepatitis C: the Live Hep C Free project
Harm Reduction Journal Open Access 21 April 2022
-
Compositions of gut microbiota before and shortly after hepatitis C viral eradication by direct antiviral agents
Scientific Reports Open Access 31 March 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Choo, Q. L. et al. Science 244, 359–362 (1989).
Hajarizadeh, B., Grebely, J. & Dore, G. J. Nat. Rev. Gastroenterol. Hepatol. 10, 553–562 (2013).
Dore, G. J. & Feld, J. J. Clin. Infect. Dis. 60, 1829–1836 (2015).
World Health Organization. Global Health Sector Strategy on Viral Hepatitis, 2016–2021 (World Health Organization, Geneva, Switzerland, 2016).
Global Burden of Disease Collaborators. Lancet 390, 1151–1210 (2017).
Scott, N. et al. J. Hepatol. 68, 932–939 (2018).
Hajarizadeh, B., Grebely, J., Matthews, G. V., Martinello, M. & Dore, G. J. J. Viral Hepat. 25, 640–648 (2018).
Moon, S. & Erickson, E. N. Engl. J. Med. 380, 607–610 (2019).
Alavi, M. et al. J. Hepatol. 71, 281–288 (2019).
Elsharkawy, A. et al. J. Hepatol. 68, 691–698 (2018).
Larney, S. et al. Lancet Glob. Health 5, e1208–e1220 (2017).
Fraser, H. et al. Addiction 113, 173–182 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. G.J.D. is an advisory board member and has received honoraria from Merck, Gilead, and Abbvie, and has received research grant funding from Merck, Gilead, and Abbvie, as well as travel sponsorship from Merck, Gilead, and AbbVie. J.G. has received research support and is a consultant for AbbVie, Cepheid, Gilead Sciences, and Merck.
Rights and permissions
About this article
Cite this article
Dore, G.J., Martinello, M., Alavi, M. et al. Global elimination of hepatitis C virus by 2030: why not?. Nat Med 26, 157–160 (2020). https://doi.org/10.1038/s41591-019-0706-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0706-x
This article is cited by
-
Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study
Addiction Science & Clinical Practice (2023)
-
The effect of hepatitis C—associated premature deaths on labour productivity losses in Spain: a ten-year analysis
The European Journal of Health Economics (2023)
-
Peer-facilitated treatment access for hepatitis C: the Live Hep C Free project
Harm Reduction Journal (2022)
-
Compositions of gut microbiota before and shortly after hepatitis C viral eradication by direct antiviral agents
Scientific Reports (2022)
-
‘Treat my whole person, not just my condition’: qualitative explorations of hepatitis C care delivery preferences among people who inject drugs
Addiction Science & Clinical Practice (2021)
